Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 82, Issue 5, Pages 595-600Publisher
WILEY
DOI: 10.1038/sj.clpt.6100362
Keywords
-
Categories
Ask authors/readers for more resources
The current 6-month tuberculosis (TB) therapy is suboptimal with significant side effects and a poor patient compliance problem that frequently selects drug-resistant organisms. The increasing drug- resistant TB problem highlights the need to develop new and more effective drugs. Significant progress has been made recently with several new drug candidates currently in clinical trials. Improved understanding of persister biology and development of persister drugs are likely to be important for developing a more effective therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available